BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

Chaoyang Sun; Jun Yin; Yong Fang; Jian Chen; Kang Jin Jeong; Xiaohua Chen; Christopher P. Vellano; Zhenlin Ju; Wei Zhao; Dong Zhang; Yiling Lu; Funda Meric‐Bernstam; Timothy A. Yap; Maureen M. Hattersley; Mark J. O’Connor; Huawei Chen; Stephen E. Fawell; Shiaw‐Yih Lin; Guang Peng; Gordon B. Mills

doi:10.1016/j.ccell.2018.01.019

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

Chaoyang Sun(The University of Texas MD Anderson Cancer Center), Jun Yin(Aurora Health Care), Yong Fang(The University of Texas MD Anderson Cancer Center), Jian Chen(The University of Texas MD Anderson Cancer Center), Kang Jin Jeong(The University of Texas MD Anderson Cancer Center), Xiaohua Chen(The University of Texas MD Anderson Cancer Center), Christopher P. Vellano(The University of Texas MD Anderson Cancer Center), Zhenlin Ju(The University of Texas MD Anderson Cancer Center), Wei Zhao(The University of Texas MD Anderson Cancer Center), Dong Zhang(The University of Texas MD Anderson Cancer Center), Yiling Lu(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Maureen M. Hattersley(AstraZeneca (United States)), Mark J. O’Connor(AstraZeneca (United Kingdom)), Huawei Chen(AstraZeneca (United States)), Stephen E. Fawell(AstraZeneca (United States)), Shiaw‐Yih Lin(The University of Texas MD Anderson Cancer Center), Guang Peng(The University of Texas MD Anderson Cancer Center), Gordon B. Mills(The University of Texas MD Anderson Cancer Center)

Cancer Cell

March 1, 2018

10.1016/j.ccell.2018.01.019

Cited by 302Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis